Tracer library / [18F]rhPSMA-7
[18F]rhPSMA-7
Also written as [18F]Ga-rhPSMA-7; [18F]rhPSMA-7; [F-18]Ga-rhPSMA-7; [F-18]rhPSMA-7; flotufolastat
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 4
What it is
- Compound class
- Radiohybrid PSMA (rhPSMA)-targeted ligand
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) targeting ligand PMID 31836686
- Clinical application
- PET imaging of prostate cancer PMID 31836686
- Theranostic pair
- [177Lu]Lu-rhPSMA-7
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | 50 ± 8% | >97% | [19F, natGa]rhPSMA-7 | 33284394 2020 EJNMMI Res a fully-automated procedure at the Klinikum rechts der Isar - RCY of 50 ± 8% |
| Scintomics GRP 2V Scintomics | custom manifold | SPE | 49.2 ± 8.6 | 97.8 ± 1.0% | rhPSMA-7/-7.3 (non-radioactive gallium…rhPSMA-7/-7.3 (non-radioactive gallium complexed) | 37819534 2023 EJNMMI Radiopharm Chem The synthesis was developed using a Scintomics GRP 2V ASU and strongly resembles the setup used for the [18F]SiTATE synthesis - a radiochemical yield of 49.2 ± 8.6% |
| Scintomics GRP 2V Scintomics | custom manifold | SPE | 49.2 ± 8.6 | 99.9 ± 0.2% (HPLC), 97.8 ± 1.0% (TLC) | Ga-rhPSMA-7 | 33484364 2021 EJNMMI Radiopharm Chem established on a GRP 2 V module (Scintomics, Fuerstenfeldbruck, Germany), employing a double-cassette setup - Overall, 98.8% (240) productions succeeded with a mean RCY of 49.2 ± 8.6%. |
| Scintomics GRP 2V Scintomics | custom manifold | SPE | 47.1 ± 9.9 | 99.96 ± 0.19% (HPLC), 97.87 ± 1.01% (TLC) | Ga-rhPSMA-7.3 | 33484364 2021 EJNMMI Radiopharm Chem established on a GRP 2 V module (Scintomics, Fuerstenfeldbruck, Germany), employing a double-cassette setup - Radiochemical yield [%]50.4 ± 7.647.1 ± 9.9 |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer.2020 · J Nucl Med · Retrospective
- How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study.2025 · Diagnostics (Basel) · Clinical study
Need this precursor?We can point you to suppliers for [18F]rhPSMA-7, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]rhPSMA-7.
Get in touchNotes
Added from reverse module search (stage 6); 4 article(s) with F-18. Stage set/updated at stage 23 from PMID 33484364: 'after a preclinical isomer selection process, [18F]Ga-rhPSMA-7.3 has entered formal clinical trials.'. | Stage 30 (2026-09-18): Stage was 'clinical trial'; normalised to 'Clinical research', original wording kept here.